Testing effectiveness (Phase 2)Study completedNCT00256711What this trial is testingPhase II Iressa Versus Vinorelbine (INVITE)Who this might be right forNon-Small-Cell Lung Carcinoma AstraZeneca 192
Testing effectiveness (Phase 2)Ended earlyNCT05091528What this trial is testingA Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersWho this might be right forHER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more Silverback Therapeutics 2
Not applicableStudy completedNCT03170284What this trial is testingObservational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Hoffmann-La Roche 150
Large-scale testing (Phase 3)Looking for participantsNCT06357533What this trial is testingPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsWho this might be right forNon-Small Cell Lung Cancer AstraZeneca 675
Testing effectiveness (Phase 2)Ended earlyNCT01526928What this trial is testingStudy to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsWho this might be right forLocally Advanced or Metastatic Non Small Cell Lung Cancer Clovis Oncology, Inc. 612
Testing effectiveness (Phase 2)Looking for participantsNCT06244771What this trial is testingA Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsWho this might be right forAdvanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more Frontier Medicines Corporation 403
Large-scale testing (Phase 3)Active Not RecruitingNCT01933932What this trial is testingAssess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCWho this might be right forLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV AstraZeneca 510
Testing effectiveness (Phase 2)Study completedNCT04143711What this trial is testingStudy of DF1001 in Patients With Advanced Solid TumorsWho this might be right forSolid Tumor, Adult Dragonfly Therapeutics 270
Early research (Phase 1)Study completedNCT04925284What this trial is testingStudy of XB002 in Subjects With Solid Tumors (JEWEL-101)Who this might be right forNon Small Cell Lung CancerCervical CancerSCCHN+8 more Exelixis 269
Large-scale testing (Phase 3)Active Not RecruitingNCT06031558What this trial is testingPhase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLCWho this might be right forNon-Small Cell Lung Cancer Shouyao Holdings (Beijing) Co. LTD 120
Early research (Phase 1)Study completedNCT02595866What this trial is testingTesting the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerWho this might be right forAIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)UnknownNCT06590194What this trial is testingPH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Who this might be right forAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Suzhou Puhe Pharmaceutical Technology Co., LTD 96
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827261What this trial is testingBL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Sichuan Baili Pharmaceutical Co., Ltd. 36
Testing effectiveness (Phase 2)Looking for participantsNCT06147570What this trial is testingHS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerWho this might be right forNonsmall Cell Lung Cancer Jiangsu Hansoh Pharmaceutical Co., Ltd. 62
Large-scale testing (Phase 3)Not Yet RecruitingNCT07754123What this trial is testingPhase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLCWho this might be right forAdvanced or Metastatic NSCLC Jiangsu Hansoh Pharmaceutical Co., Ltd. 206
Large-scale testing (Phase 3)Looking for participantsNCT07416994What this trial is testingPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer MediLink Therapeutics (Suzhou) Co., Ltd. 440
Testing effectiveness (Phase 2)Study completedNCT00777179What this trial is testingPhase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet ChemotherapyWho this might be right forNSCLC Genzyme, a Sanofi Company 117
Large-scale testing (Phase 3)Study completedNCT00078260What this trial is testingA Comparison of Two Doses of Pemetrexed in Patients Who Have Lung CancerWho this might be right forNon-Small Cell Lung Cancer Eli Lilly and Company 589
Post-approval studies (Phase 4)Study completedNCT01609543What this trial is testingTarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 62
Large-scale testing (Phase 3)Looking for participantsNCT06627647What this trial is testingA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCWho this might be right forNon-squamous Non-small Cell Lung Cancer AstraZeneca 1,160